A Russian nootropic peptide with real domestic clinical use — and a real Western evidence gap
Regulatory status
Semax is a registered medicine in Russia but has not been reviewed or approved by the FDA or EMA. Most published research comes from Russian groups, and large independent trials are lacking. This page is educational, not medical advice.
Class
Nootropic peptide
FDA Status
Not reviewed
Typical route
Intranasal
Semax is a synthetic heptapeptide based on a fragment of the hormone ACTH (the 4–10 region), with a Pro-Gly-Pro tail added to slow its breakdown so it lasts long enough to act. It was developed in Russia, where it is used clinically — usually as nasal drops — for stroke recovery, cognitive complaints, and certain optic-nerve conditions. Outside Russia it has no approved medical use and is sold only as an unregulated research chemical.
The most-cited hypothesis is that Semax raises levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — signaling molecules involved in neuron survival and plasticity. Because it derives from an ACTH fragment stripped of the hormone's usual hormonal effects, it is described as “neuroprotective without the endocrine load.” These mechanisms are supported mainly by animal and cell studies; how directly they translate to a measurable effect in healthy people is not well established.
Semax is a genuine drug with decades of clinical use in one country and a plausible biological story — not a made-up compound. But “used in Russia” is not the same standard as “proven and approved here,” and the enhancement claims that circulate online run well ahead of the independent evidence. Treat it as investigational.
Whatever you take, tracking it honestly beats guessing. Jabbit is a private, ad-free injection and protocol log.
Download on App Store